On October 24, 2019 BioXcel Therapeutics, Inc. ("BTI" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, reported that BTI’s Senior Vice President and Chief Medical Officer, Vincent O’Neill, M.D., will present the first clinical results on the safety and tolerability of BXCL701, an investigational orally available innate immunity activator, in combination with a PD-1 inhibitor (Press release, BioXcel Therapeutics, OCT 24, 2019, View Source [SID1234542503]). Data from the first patient cohort will be presented from the Company’s ongoing Phase 1b/2 study. A second patient cohort is enrolling and the Company expects to report on these additional safety findings by end of year before advancing to the Phase 2 stage of the trial.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study is designed to evaluate BXCL701 in combination with Pembrolizumab (Keytruda) for treatment-Emergent Neuroendocrine Prostate Cancer (tNEPC). The data will be presented during the 26th Annual Prostate Cancer Foundation Scientific Retreat that is being held from October 23 – 26, 2019.
Oral Presentation Details:
Title:
"BXCL701, An Orally Available Innate Immune Activator, in
Combination with Pembrolizumab for Patients with NEPC (NEPC; SCPC)"
Date:
Saturday, October 26th
Time:
8:30 a.m. – 8:45 a.m. Pacific Time
Location:
Omni La Costa Resort, Carlsbad, CA
A copy of the Company’s accompanying presentation materials that will be discussed will be available through the "Investors" page of the BTI website at View Source
About BXCL701:
BXCL701 is an investigational orally-available systemic innate immunity activator with dual mechanisms of action. It has shown single agent activity in melanoma and safety has been evaluated in more than 700 healthy subjects and cancer patients. Designed to stimulate both the innate and acquired immune systems, BXCL701 is designed to inhibit dipeptidyl peptidase (DPP) 8/9 and block immune evasion by targeting Fibroblast Activation Protein (FAP). BXCL701 is currently being developed for treatment of a rare form of prostate cancer and for pancreatic cancer in combination with other immuno-oncology agents.